IQVIA Holdings Inc. (NYSE:IQV) Shares Purchased by Andra AP fonden

Andra AP fonden lifted its position in IQVIA Holdings Inc. (NYSE:IQV) by 21.9% during the 4th quarter, Holdings Channel.com reports. The fund owned 63,000 shares of the medical research company’s stock after acquiring an additional 11,300 shares during the period. Andra AP fonden’s holdings in IQVIA were worth $12,380,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently made changes to their positions in the company. Capital Performance Advisors LLP acquired a new position in shares of IQVIA in the 3rd quarter valued at $27,000. Avior Wealth Management LLC grew its position in IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after purchasing an additional 87 shares during the period. Synergy Asset Management LLC acquired a new stake in IQVIA during the 4th quarter worth about $33,000. Assetmark Inc. grew its position in IQVIA by 612.5% during the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after purchasing an additional 196 shares during the period. Finally, Ashton Thomas Securities LLC acquired a new stake in IQVIA during the 3rd quarter worth about $57,000. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Trading Up 3.4 %

Shares of IQVIA stock opened at $191.69 on Friday. The firm has a market capitalization of $33.80 billion, a PE ratio of 25.56, a P/E/G ratio of 1.99 and a beta of 1.50. IQVIA Holdings Inc. has a twelve month low of $179.28 and a twelve month high of $261.73. The firm’s 50-day moving average price is $197.79 and its 200 day moving average price is $213.11. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have weighed in on IQV. BTIG Research downgraded IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. Stephens began coverage on IQVIA in a research report on Friday, December 20th. They set an “overweight” rating and a $250.00 price target on the stock. Truist Financial reaffirmed a “buy” rating and set a $263.00 price target (up from $261.00) on shares of IQVIA in a research report on Monday, February 10th. StockNews.com raised IQVIA from a “hold” rating to a “buy” rating in a research report on Tuesday. Finally, Robert W. Baird lowered their target price on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 21st. Four analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $249.05.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.